StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a "hold" rating on the stock.

Separately, JMP Securities restated a "market outperform" rating and issued a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Stock Performance

NASDAQ:DBVT opened at $8.75 on Wednesday. The stock's fifty day moving average is $5.64 and its 200 day moving average is $4.37. The firm has a market capitalization of $180.01 million, a PE ratio of -1.94 and a beta of -0.08. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $9.10.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The firm had revenue of $0.51 million during the quarter. Equities analysts forecast that DBV Technologies will post -7.05 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.